Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 11/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749286 | 0.93 | HTR6 (0.52) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL5750065 | 0.84 | ELANE (0.45) | JAK1 | |
| SCHEMBL38663138 | 0.83 | PDK4 (0.55) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL12874666 | 0.83 | GRM1 (0.49) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL19297054 | 0.82 | PDK4 (0.60) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL17655532 | 0.81 | PDK4 (0.61) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL3723671 | 0.81 | PDK4 (0.59) | HTR6GRM5GRM1PDK4SCN9A | |
| SCHEMBL15951022 | 0.81 | PDK4 (0.60) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL30676170 | 0.81 | GRM5 (0.61) | HTR6GRM5GRM1PDK4PDE10A | |
| SCHEMBL2631187 | 0.81 | GRM5 (0.61) | HTR6GRM5GRM1PDK4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | HTR6 139/4885GRM5 230/4885GRM1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.